Last updated on February 2018

Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)


Brief description of study

The purpose of this study is to evaluate the safety and efficacy of INCB050465 when combined with bendamustine and obinutuzumab in subjects with relapsed or refractory follicular lymphoma (FL).

Clinical Study Identifier: NCT03039114

Find a site near you

Start Over

Banner Health

Gilbert, AZ United States
  Connect »

Summit Medical Group

Morristown, NJ United States
  Connect »

Clinical Research Alliance

Lake Success, NY United States
  Connect »

Greenvile Health System

Greenville, SC United States
  Connect »

Medical College of Wisconsin

Milwaukee, WI United States
  Connect »

Rigshospitalet

Copenhagen, Denmark
  Connect »